Cambiar Investors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Cambiar Investors LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,094 shares of the biopharmaceutical company’s stock after selling 3,376 shares during the period. Cambiar Investors LLC owned 0.06% of Regeneron Pharmaceuticals worth $33,227,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in REGN. Dodge & Cox lifted its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $628,151,000. Acadian Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares during the period. Finally, Invesco Ltd. increased its position in shares of Regeneron Pharmaceuticals by 26.5% during the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after buying an additional 225,078 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.1%

NASDAQ:REGN opened at $771.25 on Wednesday. The firm has a market cap of $81.06 billion, a P/E ratio of 18.47, a P/E/G ratio of 1.99 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm has a 50-day simple moving average of $757.47 and a two-hundred day simple moving average of $647.23.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $12.46 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on REGN. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a research report on Friday, December 12th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Finally, Canaccord Genuity Group increased their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $784.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.